RxDoctor Payments Data

David Talley

Optometrist · Memphis, TNNPI 1982697058

Payments from drug & device makers

$2,152in general payments, 2019–2025

Across 61 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$493
  • Glaukos Corporation$377
  • Alcon$274
  • ANI Pharmaceuticals, Inc.$115
  • Dompe US, Inc.$115
  • NEW World Medical,inc.$109
  • plus $669 from 11 others

What the payments were for

  • Food & beverage$2,13499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,152 in reported general payments places this provider in the 75th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$68,980
Medicare patients
304
Services billed
941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost61$43,764
CombiganBrimonidine Tartrate/Timolol31$13,227
Loteprednol Etabonate53$9,460
RhopressaNetarsudil Mesylate11$9,051
Alphagan PBrimonidine Tartrate18$8,693
SimbrinzaBrinzolamide/Brimonidine Tart12$5,625
RocklatanNetarsudil Mesylat/Latanoprost12$5,351
Travoprost20$3,700
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$3,341
Brinzolamide12$1,926
Latanoprost139$1,438
Prednisolone Acetate24$1,275
Acetazolamide21$762
Brimonidine Tartrate27$753
Timolol Maleate39$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$493$65,685110 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$22$9,46053 claims
AlconSimbrinza$274$5,62512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →